NASDAQ: SNYRSynergy Chc Corp Stock
$2.49-0.01 (-0.4%)
Updated Apr 17, 2025
SNYR Price
$2.49
Fair Value Price
N/A
Market Cap
$21.79M
52 Week Low
$1.30
52 Week High
$10.00
P/E
8.89x
P/B
-1.31x
P/S
0.96x
PEG
0.13x
Dividend Yield
N/A
Revenue
$34.83M
Earnings
$2.12M
Gross Margin
67.9%
Operating Margin
18.18%
Profit Margin
6.1%
Debt to Equity
-1.98
Operating Cash Flow
-$5M
Beta
-0.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNYR's potential to beat the market
- SNYR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Distribution
Industry Rating
A
SNYR
RankedUnranked of 6
RankedUnranked of 6
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $64.73 | B | |
| $134.71 | B | |
| $286.74 | B |
Be the first to know about important SNYR news, forecast changes, insider trades & much more!
SNYR News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNYR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNYR ($2.49) is trading below its intrinsic value of $8.18, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SNYR is good value based on its earnings relative to its share price (8.89x), compared to the US market average (27.98x)
P/E vs Market Valuation
SNYR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SNYR due diligence checks available for Premium users.
Valuation
SNYR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.89x
Industry
32.31x
Market
27.98x
SNYR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SNYR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SNYR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.31x
Industry
-306.01x
SNYR price to earnings growth (PEG)
For valuing profitable companies with growth potential
SNYR is good value based... subscribe to Premium to read more.
PEG Value Valuation
SNYR's financial health
Profit margin
Revenue
$10.3M
Net Income
$105.7k
Profit Margin
1%
SNYR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SNYR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.3M
Liabilities
$33.0M
Debt to equity
-1.98
SNYR's short-term liabilities ($17.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNYR's short-term assets ($16.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNYR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNYR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$3.9M
SNYR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNYR vs Medical Distribution Stocks
Synergy Chc Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.